News | Artificial Intelligence | June 13, 2019

iCAD Introduces ProFound AI for 2D Mammography in Europe

Company to showcase its newest artificial intelligence software solution at the SIFEM Medical Conference in France

iCAD Introduces ProFound AI for 2D Mammography in Europe

June 13, 2019 — iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence (AI) platform and follows the launch of ProFound AI for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and U.S. Food and Drug Administration (FDA)-cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference June 13-15, 2019, in Lille, France.

ProFound AI is available for both mammography and tomosynthesis modalities; it is a high-performance, deep-learning, breast cancer detection and workflow solution that offers benefits to radiologists and patients alike. ProFound AI for DBT is clinically proven to improve cancer detection rates by 8 percent, reduce unnecessary patient recall rates by 7.2 percent, and slash reading time for radiologists by 52.7 percent and up to 57.4 percent for dense breast 3-D image analysis.1

“The arrival of the ProFound AI platform has completely changed the way we read tomosynthesis cases. It is a very powerful and extremely useful tool that improves our diagnostic confidence; especially for subtle lesions and dense breasts,” according to Patrick Toubiana, M.D., radiologist, president and cofounder at the C.S.E. Centre Imagerie Médicale Numérique in Paris. “In addition, ProFound AI allows us to optimize our workflow for better reading comfort and a reduction of the interpretation time of the tomosynthesis slices. Today, ProFound AI is a real asset in our daily practice that we could not do without.”

ProFound AI for 2D Mammography and ProFound AI for DBT were designed to rapidly and accurately analyze each image. They provide radiologists with key information, such as certainty of finding lesion and case scores, which assists in clinical decision-making and prioritizing caseloads. Featuring the latest in deep learning AI, the platform also allows for continuously improved performance via ongoing updates.

ProFound AI for 2D Mammography is pending CE Mark in the EU.

For more information: www.icadmed.com

Related Content

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

VIDEO: How iCad Uses AI to Speed Breast Tomosynthesis

 

Reference

Hoffmeister J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed June 4, 2019 via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf

Related Content

The interior of the German air force Airbus A-310 Medivac in Cologne, Germany, before its departure to Bergamo, Italy, March 28 to being ferrying COVID-19 patients to Germany for treatment to aid the Italians, whose healthcare system has been overwhelmed by the rapid spread of the coronavirus pandemic. Bundeswehr Photo by Kevin Schrief.

The interior of the German air force Airbus A-310 Medivac in Cologne, Germany, before its departure to Bergamo, Italy, March 28 to being ferrying COVID-19 patients to Germany for treatment to aid the Italians, whose healthcare system has been overwhelmed by the rapid spread of the coronavirus pandemic. Bundeswehr Photo by Kevin Schrief. Find more images from the COVID-19 pandemic.

 

Feature | Coronavirus (COVID-19) | April 08, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2  The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ve

 The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Contextual detail and considerations for imaging with CXR (chest radiography) versus CT (computed tomography) are presented in the text. (Pos=positive, Neg=negative, Mod=moderate). [Although not covered by this scenario and not shown in the figure, in the presence of significant resources constraints, there is no role for imaging of patients with mild features of COVID-19.] Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | April 07, 2020
April 7, 2020 — A multinational consens...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Chest CT findings of pediatric patients with COVID-19 on transaxial images. (a) Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe

Chest CT findings of pediatric patients with COVID-19 on transaxial images. Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe. Image courtesy of Radiology: Cardiothoracic Imaging

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Children and teenagers with COVID-19...
A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms
Feature | Breast Imaging | April 06, 2020 | By Samir Parikh
A recent study earlier this year in the journal Nature,
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Feature | Breast Density | April 03, 2020 | By Dayna Williams M.D., Shivani Chaudhry, M.D., and Laurie R. Margolies, M.D.
Breast cancer is the most common cance
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...